An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to FDG PET/CT Imaging
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary) ; Tc 99m tilmanocept (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions; Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 08 Aug 2017 According to a Navidea Biopharmaceuticals media release, interim results from this trial are expected by year-end 2017.
- 09 May 2017 Status changed from not yet recruiting to recruiting, according to a Navidea Biopharmaceuticals media release.
- 01 Feb 2017 New trial record